MedPath

Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008

Not Applicable
Terminated
Conditions
Stroke
Interventions
Device: radio frequency-controlled (RF) Microstimulator (RFM) Gait System
Registration Number
NCT00864708
Lead Sponsor
US Department of Veterans Affairs
Brief Summary

The purpose of the study is to investigate new Technology for recovery of ankle walking function after stroke.

Detailed Description

Background and Purpose: Conventional rehabilitation does not restore normal, upper limb function or normal gait to many stroke survivors. Functional neuromuscular stimulation (FNS) has shown promise for functional enhancement of both upper and lower limb motor control following stroke. Gains included muscle activation latencies, strength, coordination, upper limb functional tasks, gait kinematics, walking endurance, and quality of life. The purpose of the proposed work is to test the radio frequency-controlled (RF) Microstimulator (RFM) Gait System regarding system performance and subject response to treatment.

Methods: This is a feasibility study in which up to four subjects will receive the (RFM) Gait System. Up to ten RFMs will be placed for a given subject. An RFM ankle muscle system will be used to train ankle gait components. A separate RFM system will be used to train knee gait components. Subjects will be treated for 6 months, four sessions/wk. Primary outcome measures for the RFM Gait System will be: kinematic swing phase gait components and walking endurance. Secondary outcome measures will include: strength, coordination, spasticity, function, and quality of life. Data collections will occur at months 1, 3 and 6, and for follow-up times up to a year after the end of treatment. The results of the RFM ankle system have the potential to provide a new technology for ankle muscle gait components.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • Sufficient endurance to participate in rehabilitation sessions.
  • Medically Stable
  • Age >21 years.
  • Inability to perform normal ankle coordinated gait components.
  • Participants should be able to walk and keep balance without physical assistance from another person
Exclusion Criteria
  • Acute or progressive cardiac, renal, respiratory, neurological disorders or malignancy.
  • Lower motor neuron damage or radiculopathy
  • Allergy or contraindication to anesthesia, Versed, (or comparable substitute.
  • Active implantable device (e.g. pacemaker, implantable cardiac defibrillator, neurostimulator, or drug infusion device.
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Arm 1radio frequency-controlled (RF) Microstimulator (RFM) Gait Systemradio frequency-controlled (RF) Microstimulator (RFM) Gait System
Primary Outcome Measures
NameTimeMethod
Walking Endurance (6MWT)Day 1 and at 3 months, following treatment

The Six Minute Walk Test (6MWT) is a measure of the distance measured in feet ambulated by the participant during six minutes. A further distance walked in 6 minutes indicates improvement on the measure.

Kinematic Gait MeasuresDay 1 and at 3 months, following treatment

assessment of the lower limb kinematics during ambulation at chosen speed.

Secondary Outcome Measures
NameTimeMethod
Fugl-Meyer Lower Extremity ScoreDay 1 and at 3 months, following treatment

Fugl-Meyer Lower Extremity Score (FMLE) is an itemized measure of lower extremity coordination following stroke. Scores for the FMLE range from 0 (most impaired) to 34 (normal).

Ashworth ScaleDay 1 and at 3 months, following treatment

The Ashworth Scale is a measure of muscle spasticity; muscle groups are graded from 0 (no spasticity) to 4 (greatest spasticity/contracture). The lower limb muscle groups are summed for a total lower limb Ashworth score. A lower score indicates better performance. (range is 0-40)

Stroke Impact Scale (SIS)Day 1 and at 3 months, following treatment

The SIS is a measure of Quality of Life/Life Role Participation following stroke. Each item in a domain is scored between 0 and 5. A higher score indicates better performance (range 0-295).

Manual Muscle Testing (MMT)Day 1 and at 3 months, following treatment

This is a measure of strength of the various muscle groups of the lower limb. Each is graded on a 0 to 5 scale; the final score is the summed total of the lower limb muscle groups tested. (score range of summed muscles is 0-50, with 50 being the maximum highest score)

Trial Locations

Locations (1)

VA Medical Center, Cleveland

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath